Sotigalimab

DB16413InvestigationalProtein Based Therapies

Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).

Mechanism
Curator reviewed
Also known as
CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M · IMMUNOGLOBULIN G1 (270-GLUTAMIC ACID, C-TERMINAL-LYSINE-CLIPPED), ANTI-(HUMAN CD40 ANTIGEN) (HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .KAPPA.-CHAIN, DIMER
Code names
APX-005 · APX-005M · EPI-0050

Resolves to

Compound
UNIIJEA93WJ5DGCAS2305607-45-6
Targets
P25942CD40

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
15Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Sotigalimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In